The mechanism by which glucocorticoids alleviate renal inflammatory disorders remains incompletely understood. Here, we report that the efficacy of glucocorticoids in ameliorating FSGS depends on the capacity to expand myeloid-derived suppressor cells (MDSCs). After glucocorticoid treatment, the frequency of CD11b and kidney also increased after glucocorticoid treatment. The induced MDSCs from glucocorticoid-treated mice strongly suppressed T cells, dendritic cells, and macrophages but induced regulatory T cells in spleen, KDLNs, and kidney. Moreover, glucocorticoid treatment suppressed doxorubicin-induced T cell proliferation, dendritic cell and macrophage infiltration, and proinflammatory cytokine production, whereas this protective effect was largely abolished by depleting MDSCs using anti-Gr-1 antibody. Finally, the adoptive transfer of induced MDSCs into the doxorubicin-treated mice not only confirmed the protective role of MDSCs in doxorubicin-induced renal injury but also showed that the transferred MDSCs rapidly migrated into the lymphocyte-accumulating organs, such as the spleen and KDLNs, where they suppressed T cell proliferation. Taken together, these results demonstrate that glucocorticoid treatment ameliorates FSGS by expanding functional MDSCs and that this rapid elevation of MDSCs in peripheral blood may serve as an indicator for predicting the efficacy of glucocorticoid treatment.
FSGS, one of the leading causes of ESRD, 1 accounts for approximately 20% of cases of nephrotic syndrome in children and 40% of such cases in adults. 2 The causes of FSGS are very complicated, involving genetic abnormalities, immunologic abnormalities, viral infections, decreased nephron numbers, and hyperfiltration. 3 Clinical observations suggested that FSGS is induced by immune factors, in which T cell dysfunction played an important role. In 1974, Shalhoub 4 first hypothesized that idiopathic nephrotic syndrome (minimal-change disease and FSGS) was produced by T cell dysfunction, resulting in the secretion of chemical mediators toxic to the glomerular basement membrane. Various subsets of T cells, including CD8 cells and CD4 helper cells of Th1, Th2, IL17-producing Th17 and regulatory T cells (Tregs), are involved in glomerular disease. [5] [6] [7] [8] [9] The cytokines released by Th17 cells further induce other cells to secret proinflammatory chemokines that attract leukocytes and activate resident glomerular cells. 10 The initial treatment option of primary FSGS in children and young adults is often limited to high-dosage synthetic glucocorticoid (GC) analogues despite their multiple adverse effects. 11, 12 Approximately 30%-60% of patients with primary FSGS respond to an initial course. 13, 14 Although the mechanism remains unclear, the number of leukocytes in the peripheral blood of GC-sensitive patients was generally increased after GC treatment. 13 In contrast, patients who are steroid resistant have a chronic disease and are at an increased risk of progressing to ESRD and complications related to uncontrolled nephrotic syndrome. 11, 13, 15 GCs can also effectively promote apoptosis of leukemia cells, trigger complex antiinflammatory actions, and induce apoptotic death of peripheral and developing T cells. [16] [17] [18] However, although the molecular mechanisms underlying GC treatment have been extensively investigated, how exogenous GCs affect peripheral immune cells in FSGS or other renal diseases remains largely unknown.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that can suppress T cell responses. 19, 20 In mice, the phenotype of MDSCs is characterized by the coexpression of Ly-6C/G and CD11b and can be subdivided into granulocytic CD11b + Ly-6G + Ly-6C low MDSCs and monocytic CD11b + Ly-6G -Ly-6C high MDSCs. Granulocytic MDSCs suppress T cell proliferation primarily through reactive oxygen species, whereas monocytic MDSCs suppress T cell proliferation by high levels of nitric oxide produced from inducible nitric oxide synthase. 19, 21 Because of the lack of markers of mature myeloid and lymphoid cells, human MDSCs are generally defined as cells that express CD11b and the common myeloid marker CD33. 22, 23 While both groups of MDSCs are HLA-DR low/neg and CD33 + , human monocytic MDSCs are generally CD14 positive, and granulocytic MDSCs express CD15. Human MDSCs were reported for the first time in patients with head and neck cancer. 24 Under tumor conditions, human MDSCs were widely found to be expanded. 22, 23, 25, 26 Recent studies indicated that the accumulation of MDSCs was also related to inflammatory and autoimmune diseases, including inflammatory bowel disease, 27 type 1 diabetes, 28 multiple sclerosis, 29 and hepatitis B and C virus infection. 30 However, the direct anti-inflammatory role and mechanism of MDSCs in FSGS remain inconclusive.
In the present study, we hypothesized that the expansion of immunosuppressive MDSCs might play an essential role in GC-mediated therapy for FSGS disease. The patients with FSGS were classified as GC sensitive or GC insensitive on the basis of clinical diagnosis. MDSCs in the peripheral blood of these patients with FSGS were assessed before and after GC treatment. The effects of MDSCs on experimental renal injury were determined by treating mice with GC or directly adoptivetransferring MDSCs into doxorubicin-treated mice. Our results demonstrated that MDSCs play a critical protective role against renal injury and serve as a major mechanism underlying the GC-based therapy for patients with FSGS. Leukocytosis has long been recognized in GC-treated nephrotic diseases, although the underlying mechanism is largely unknown. 31 To explore the molecular mechanism of this phenomenon, the peripheral blood of patients with FSGS was collected before and 7-14 days after GC therapy. These patients were then continuously treated with GCs. At the end of the 12-16 weeks of GC treatment, these patients were divided into GC-sensitive and GC-insensitive groups according to clinical diagnoses. Clinical measures and histologic injury at baseline are shown in Tables 1 and 2 , respectively. In general, blood samples from 86 new patients with FSGS sensitive to GC treatment, 23 new patients insensitive to GC treatment, and 13 healthy people were collected. As shown in Table 1 , urine protein (U-pro), total cholesterol (TC), and triglyceride (TG) were significantly downregulated in GC-sensitive patients after GC treatment, while serum albumin was significantly upregulated. In contrast, these measures did not significantly differ between GC-insensitive patients before and after GC treatment. There were also no significant differences between GC-sensitive patients and GC-insensitive patients for baseline clinical and pathologic features, including electron microscopy findings. 
RESULTS
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We also assayed the MDSCs in the peripheral bloods of patients with minimal-change disease who are GC sensitive or GC insensitive before and after GC therapy. In this experiment, 48 patients with minimal-change disease were divided into GC-sensitive (43 of 48) and GC-insensitive (5 of 48) groups according to clinical diagnoses (Supplemental Table 1 ). At pathologic examination, the patients with minimal-change disease were diagnosed with normal appearance of glomeruli and lack of tubulointerstitial fibrosis on light microscopy, whereas these patients were diagnosed with extensive effacement of foot processes of the podocytes on electron microscopy. As shown in Supplemental Figure 1 , A and B, the levels of
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+ HLA-DR 2 CD14 2 CD15 + cells were significantly increased in the peripheral blood of GC-sensitive patients with minimal-change disease but not GC-insensitive patients with that disease. Moreover, the isolated HLA-DR
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+ cells from the peripheral blood of GC-sensitive patients with minimalchange disease also showed a strong inhibition on T cell proliferation (Supplemental Figure 1C) . Therefore, the expansion of MDSCs is not specific to FSGS but likely a common phenomenon responding to effective treatment of GC. and the expansion of mononuclear cells and T cells in the interstitial compartment. 7, 9, 32 In this experiment, 8-week-old male BALB/c mice that weighed 20-22 g were injected intravenously with saline (control) or doxorubicin, 10 mg/kg. As shown in the diagram of the experimental design (Supplemental Figure 2A ), following doxorubicin administration, urine was collected on days 0, 3, 7, and 14, and the mice were euthanized and the sera were collected. Evidence collectively indicated that the doxorubicin-induced FSGS mice model was successfully developed. The doxorubicin-treated group of mice showed prominent increase in proteinuria and serum creatinine compared with the control (Supplemental Figure 2 , B and C). The peak urinary albumin level was observed at 1 week. Electron microscopy and periodic acid-Schiff staining results (Supplemental Figure 2 , D and E) revealed that the doxorubicin treatment caused a severe loss of foot processes, glomerular sclerosis, and tubular damage.
To examine the potential role of MDSCs in doxorubicininduced renal injury, the levels of CD11b MDSCs derived from doxorubicin-treated mice, MDSCs were purified from mouse spleen after doxorubicin treatment and then co-cultured with CFSE-labeled T cells. As shown in Figure  2C , Gr-1 + cells purified from mouse spleen after doxorubicin treatment for 2 weeks strongly suppressed T cell proliferation in a dose-dependent manner. In agreement with that, MDSCs induced in doxorubicin-treated mice were mainly granulocytic MDSCs and suppressed T cell proliferation via reactive oxygen species pathway, 34 addition of reactive oxygen species inhibitor apocynin (APO) but not nitric ocide inhibitor NG-methyl-Larginine, acetate salt (L-NMMA) abolished the inhibitory effect of Gr-1 + cells ( Figure 2D ). A substantial amount of H 2 O 2 was generated in Gr-1 + cells from doxorubicin-treated mice but not Gr-1 + cells from control mice following phorbol myristate acetate (PMA) stimulation ( Figure 2E ). We also assayed T cells and their activity in doxorubicin-treated mice and found that CD4 + and CD8 + T cells in the mouse spleen and blood ( Figure 2F ), as well as the secreted cytokine IL-6, TNF-a, IFN-g, and IL-4 ( Figure 2G ) were upregulated.
GCs Protect Mice from Doxorubicin-Induced Renal Injury and Induce the Expansion of MDSCs
The effects of GCs on GN and their ability to expand the immunosuppressive MDSCs were examined. Mice were treated with synthetic dexamethasone at different concentrations (0.1, 1.0, 10 mg/kg) every other day after the induction of doxorubicininduced mouse renal injury ( Figure 3A) . The results showed that dexamethasone treatment strongly increased the frequency of CD11b + Gr-1 + MDSCs in mouse BM, spleen, blood, KDLNs, and kidney in a dose-dependent manner ( Figure 3B ). Furthermore, Gr-1 + MDSCs isolated from the spleen and KDLNs of mice treated with 1 mg/kg dexamethasone also displayed the ability to inhibit T cell proliferation in vitro ( Figure 3C) . Accordingly, the populations of CD4 + and CD8 + T cells in mouse spleen and blood were strongly downregulated by dexamethasone treatment ( Figure 3D ). The serum levels of IL-6, TNF-a, IFN-g, and IL-4 were examined and found to be significantly downregulated by GCs ( Figure  3E ). Next, we compared the doxorubicininduced renal injury in mice treated with or without 1 mg/kg dexamethasone. As shown in Figure 3 , F-I, dexamethasone treatment strongly attenuated the doxorubicininduced renal injury in mice, accompanied by a lower levels of urinary albumin ( Figure  3F ) and serum creatinine ( Figure 3G ), less glomerular sclerosis and tubular damage ( Figure 3 , H and I), less foot processes loss or infusion ( Figure 3J ), and less body weight loss (Supplemental Figure 3) . These results indicate that the protection that dexamethasone provides against doxorubicin-induced renal injury may depend on the induction of MDSCs.
To directly view the effect of MDSCs on the attenuation of doxorubicin-induced renal injury in the mouse model, we isolated BM from BALB/c mice, induced the expansion of Bm-MDSCs by GM-CSF and IL-6, 35 and then injected these BM-MDSCs into mice treated with doxorubicin every 3 days ( Figure 4A ). The transfer of BM-MDSCs strongly attenuated the doxorubicin-induced renal injury compared with that of mice without the BM-MDSC transfer. In the BM-MDSC group, mice showed a lower level of proteinuria ( Figure 4B ), lower serum creatinine ( Figure 4C ), less glomerular sclerosis and tubular damage ( Figure  4D ), less loss or fusion of foot processes ( Figure 4E ), and less body weight loss (Supplemental Figure 3) , suggesting a protection of transferred BM-MDSCs against Figure 4F ). As expected, adoptive transfer of BM-MDSCs markedly decreased the numbers of CD4 + and CD8 + T cells in the spleen and blood ( Figure 4G ) and the levels of serum IL-6, TNF-a, IFN-g, and IL-4 ( Figure 4H ) in doxorubicintreated mice.
To trace the transferred MDSCs in mice under the condition of doxorubicin treatment, BM-MDSCs were induced from green fluorescent protein (GFP) transgenic mice. The tissue distribution of GFP-positive BM-MDSCs in the host mice was directly visualized following tissue dissection. In the doxorubicintreated mice, GFP transgenic BM-MDSCs were readily detected in the mouse spleen, KDLN and kidney at 3 hours after injection ( Figure 5, A and B) . In contrast, no GFP transgenic BM-MDSCs were detected in the spleen, KDLN and kidney of mice without ADR treatment. To test the inhibitory capacity of the transferred MDSCs, GFP-positive MDSCs were isolated from mouse KDLN and spleen at 2 weeks after injection. As shown in Figure 5C , the isolated GFP-positive MDSCs significantly inhibited T cell proliferation. These results suggested that the transferred BM-MDSCs readily migrated to certain organs, particularly to where lymphocytes accumulated under inflammatory conditions.
Depletion of MDSCs Aggravated Doxorubicin-Induced Renal Injury and Abolished the Protective Effect of GCs
To confirm the protective effect of MDSCs on doxorubicininduced renal injury, doxorubicin-induced mouse renal injury was monitored after depleting MDSCs using an anti-Gr-1 antibody. 36 As shown in Figure 6A , mice were divided into five groups: mice administered with saline, mice treated with doxorubicin; mice treated with doxorubicin and dexamethasone; mice treated with doxorubicin and an anti-Gr-1 antibody; and mice treated with ADR, an anti-Gr-1 antibody and dexamethasone. Renal function of each mouse was measured at the end of the experiment. As shown in Figure 6 , B and C, the levels of urinary albumin and serum creatinine were dramatically increased in mice with MDSC depletion compared with that of mice without MDSC depletion. Examination of renal pathologic findings showed that MDSC depletion in mice treated with doxorubicin resulted in more severe glomerular sclerosis and tubular damage ( Figure 6 , D and E), more loss of foot processes, and more vacuolization compared with mice without MDSC depletion ( Figure 6F) . Furthermore, as shown in Supplemental Figure 3 , mice in the MDSC-depleted group showed more bodyweight loss.
Next, the effect of anti-Gr-1 antibody administration on the numbers of MDSCs, T cells, and cytokines was examined. As expected, the administration of anti-Gr-1 antibody effectively downregulated the frequency of CD11b + Gr-1 + MDSCs in BM, spleen, blood, KDLNs, and kidney ( Figure 6G ). The depletion of MDSCs led to a marked increase in the frequencies of CD4 + and CD8 + T cells in both spleen and blood of doxorubicin-treated mice ( Figure 6H ). The serum levels of IL-6, TNF-a, IFN-g, and IL-4 were also increased in MDSCdepleted mice ( Figure 6I ). Interestingly, dexamethasone did not reverse doxorubicin-induced renal injury in MDSCdepleted mice, as indicated by severe loss of foot processes, glomerular sclerosis and tubular damage, more inflammatory T cell infiltration, and higher concentrations of proinflammatory cytokines, suggesting that MDSCs play an essential role in dexamethasone-mediated protection against doxorubicininduced renal injury.
MDSCs Attenuated Doxorubicin-Induced Renal Injury via Inducing Tregs
Given that MDSCs decreased the levels of proinflammatory cytokines in doxorubicin-treated mice, we next investigated whether the protective role of MDSCs depends on their capacity to induce Tregs or suppress other inflammatory leukocytes. As shown in Figure 7 , A-C, and Supplemental Figure 4, Figure 8, A and B) . These results suggest that MDSCs may attenuate doxorubicin-induced renal injuries by modulating Tregs and immune cells. 
DISCUSSION
Although the cause of FSGS is complicated, it has long been considered a T cell-driven disease in which lymphokines, the "circulating factor," induce proteinuria and podocyte functional and structural derangement. In FSGS, monocytes and macrophages, T cells, and their mediators, such as Tregs, play an important role in the inflammatory process. The variety of inflammatory cells infiltrating into the interstitium and the correlation with the degree of renal insufficiency are important features of human and experimental FSGS. [37] [38] [39] Doxorubicin-induced renal injury is a common mouse or rat model resembling FSGS. 40 Although doxorubicin-induced renal injury is usually ascribed to a direct toxic effect of doxorubicin, an inflammatory mechanism for doxorubicin-induced podocyte injury has been extensively reported. 7, 40, 41 Renal expression of TNF-a, IL-1b, and monocyte chemotactic protein-1 was increased in response to doxorubicin. 41 Inflammatory CD8 + T cells 7 and NF-kB 40 play substantial roles in doxorubicin-induced renal injury. Using a doxorubicin-induced mouse model, Wang and coworkers 42 reported the involvement of CD4 + T cells in the pathogenesis of the interstitial lesion in doxorubicin nephropathy. Amore et al. 43 suggested that an imbalance of T cell subsets induced by doxorubicin is likely the initial step to the appearance of proteinuria and nephropathy. By inhibiting T cell activities, Tregs protected animals against chronic renal injury induced by doxorubicin. 9 The main feature of MDSCs is an immunosuppressive function that MDSCs can suppress T cell proliferation and leukocyte inflammatory responses. However, although MDSCs have been reported to regulate innate and adaptive immunity in various inflammatory and autoimmune diseases, few studies have explored their roles in modulating chronic renal diseases. Here, we present the first evidence of the MDSCs responding to GC treatment and the effectiveness of GC treatment in human FSGS. Our results showed that MDSCs could be induced by GC treatment and protected mice against doxorubicin-induced renal functional impairment and structural derangement. Because the MDSCs expanded at the first week and then gradually reduced at later stage, the elevation of MDSCs may play a critical role in the initial host resistance to doxorubicininduced renal injuries.
As an immune suppressor, GCs are effective anti-inflammatory treatments for asthma, rheumatoid arthritis, inflammatory bowel disease, and autoimmune diseases. 44 FSGS has long been regarded as a T celldriven condition. 4 Systemic administration of GCs can result in GN remission. 45 Accompanied by the remission of GN, a certain degree of leukocytosis has been observed in patients with nephrotic syndrome after GC treatment. 31, 46 GCs can suppress inflammation and immune function through various mechanisms, including interfering with the function of T lymphocytes, reducing the recruitment of monocytes and macrophages, and inhibiting the release of inflammatory cytokines by immune cells. [47] [48] [49] A recent study by Varga et al. 48 reported that GC treatment could induce an anti-inflammatory monocyte subset in mice that resemble myeloid-derived suppressor cells. By assessing the MDSCs in patients with FSGS who are sensitive or insensitive to GCs, we demonstrate for the first time that the expansion of immunosuppressive MDSCs may be a major mechanism underlying the protective or therapeutic effect of GCs in FSGS. Compared with GC-insensitive patients with FSGS, those who are GC sensitive produce significantly more MDSCs at the early stage of GC treatment. These rapidly induced MDSCs would suppress the proliferation and activation of T cells and thus attenuate the inflammation and renal injury in GC-sensitive patients. Given that MDSCs will eventually differentiate into mature neutrophils and monocytes, this may explain why leukocytosis is often observed after GC treatment in patients with nephritic syndrome patients. 33 We also confirmed the essential role of MDSCs in the GC-mediated protection of renal injury using a doxorubicin-induced mouse renal injury model. Although the response of doxorubicin-treated mice to steroid has not been characterized, several studies have shown altered expression of plasma proteins 50 and podocyte proteins 51 and an attenuation of glomerular filtration barrier damage 52 in rat nephropathy model following steroid treatment. Our results show that dexamethasone treatment strongly promotes the expansion of MDSCs in mouse BM, spleen, peripheral blood, KDLNs, and kidney in the presence of doxorubicin. Of note, when MDSCs in mice are depleted by injecting the anti-Gr-1 antibody, the effect of dexamethasone on ameliorating doxorubicininduced renal injury and suppressing T cellmediated immune response is largely abolished. These results confirm that the generation of immunosuppressive MDSCs may serve as an important mechanism by which GCs suppress chronic inflammation and autoimmunity. A cell tracing experiment provides direct evidence that under inflammation, exogenous MDSCs can migrate to lymphocyte-accumulating organs, such as the spleen and KDLNs, where they suppress the proliferation of T cells. Given that the effect of GCs on attenuating renal injuries and chronic inflammation depends on MDSCs, the level of MDSCs in patients' peripheral blood after GC treatment may provide an early indicator to predict the efficacy of GC-based therapy for individual patients with FSGS. In the present study, MDSCs were depleted by anti-Gr-1 antibody treatment. Anti-Gr-1 antibody also reduced the production of neutrophils and monocytes. Because neutrophils and monocytes are major proinflammatory cells under acute inflammation, deficient production of neutrophils and monocytes should attenuate the inflammation and the inflammationinduced tissue injury. However, our data clearly showed that anti-Gr-1 antibody treatment largely abolished the protective effect of dexamethasone on doxorubicin-induced renal injury. The mice treated with dexamethasone and anti-Gr-1 antibody showed more severe doxorubicin-induced renal injury and inflammation compared with the mice treated with dexamethasone alone. The effect of anti-Gr-1 antibody on aggravating doxorubicin-induced renal injury suggests that reduction of neutrophils and monocytes by anti-Gr-1 antibody plays a minor role in abolishing the protection of dexamethasone on doxorubicin-induced renal injury.
In addition to the abnormalities of subsets of T cells in FSGS, the role of cytokines in the development of FSGS has also attracted attention. IL-4 production by Th2 cells was upregulated in patients with membranous nephropathy and correlated with the severity of proteinuria. 53 Yano et al. 54 found that the levels of IL-4, IL-10, IFN-g, IL-1b, and IL-12 in the supernatants of peripheral blood mononuclear cells from patients with nonIgA mesangial proliferative GN are higher than those in healthy controls and that the level of IFN-g correlated with the degree of renal injury. Futrakul et al. 55 reported that the immune imbalance caused by decreased antiinflammatory factor dominated the mechanism of FSGS. In the present study, we also found an increase in IL-6, TNF-a, IFN-g, and IL-4 levels in mice with doxorubicininduced renal injury, whereas adoptive transferred BM-MDSCs or MDSC-expanding dexamethasone strongly decreased the levels of these cytokines. Thus, MDSCs may attenuate doxorubicin-induced mouse renal injuries by controlling the production of inflammatory cytokines. In summary, our study demonstrates that GC-induced or adoptively transferred MDSCs protect mice from doxorubicin-induced injury via suppressing CD4 + and CD8 + T cells, CD11c 
CONCISE METHODS
Patients
The Human Subjects Committee of Jinling Hospital, Nanjing University School of Medicine, Nanjing, China, approved all protocols concerning the use of patient samples in this study. Each donor provided a signed consent form. Blood samples were collected from consenting healthy donors and patients with FSGS (with signed consent form) for MDSC analysis. All patients were diagnosed by renal biopsy at National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine. The patients were selected according to the following criteria: (1) proteinuria .0.4 g/24 hours; (2) serum creatinine ,265.2 mmol/L; (3) global glomerulosclerosis with ,50% of glomeruli; and (4) absence of obesity, diabetes mellitus, hepatitis C virus infection, hepatitis, and malignant tumors. In this study, 13 normal controls, 86 patients with FSGS and 43 patients with minimal-change disease sensitive to GC treatment, and 23 patients with FSGS and 5 patients with minimal-changed disease insensitive to GC treatment were enrolled.
Mice
Animal maintenance and experimental procedures were carried out in accordance with the National Institutes of Health Guidelines for Use of Experimental Animals and approved by the Medicine Animal Care Committee of Nanjing University. Eight-week-old male BALB/c mice 
Reagents and Antibodies
Murine IL-6 and GM-CSF cytokines were obtained from PEPRO-TECH (Rocky Hill, NJ). Doxorubicin hydrochloride, dexamethasone, APO, and L-NMMA were obtained from Sigma-Aldrich (St. Louis, MO). PE-conjugated anti-mouse CD11b and PerCP/Cy5.5 anti-mouse Gr-1 were purchased from Biolegend (San Diego, CA). FITC-conjugated rat anti-mouse CD4 and CD8a antibodies were purchased from BD Biosciences (Franklin Lakes, NJ). APC-conjugated anti-mice CD3, APC-conjugated anti-human HLA-DR, Fluor 488-conjugated anti-human CD14, PE-conjugated anti-human CD11b, and PerCP/Cy5.5 anti-human CD15 were purchased from Biolegend.
Purified anti-mouse CD4, CD8a, F4/80, and Ly-6G/Ly-6C (Gr-1) antibodies for immunohistochemistry were also purchased from Biolegend. Purified anti-mouse CD11c and FoxP3 antibodies for immunohistochemistry were purchased from eBioscience.
Flow Cytometry Analysis
KDLN cells and spleen cells were isolated from mice using standard methods. In brief, KDLNs and spleen were finely minced, grinded, passed through 70-mm nylon cell strainer, centrifuged, and depleted the red blood cells. 
Adoptive Transfer of BM-Derived MDSCs
BM-derived MDSCs were prepared as previously described. 49 In brief, cells were plated into dishes using RPMI 1640 medium supplemented with 2 mM L-glutamine, 10 mM HEPES, 20 mM 2-mercaptoethanol, 150 U/ml streptomycin, 200 U/ml penicillin, and 10% FBS and stimulated with combinations of GM-CSF (40 ng/ml) and IL-6 (40 ng/ml). Cells were cultured at 37°C in a 5% CO 2 -humidified atmosphere for 4 days, and 5310 6 induced BM-MDSCs were injected into the tail vein of each BALB/c mouse. Mice were divided into three groups (five mice in each group): (1) the control group (which received saline only), (2) the doxorubicin group (which received doxorubicin only), and (3) the doxorubicin+MDSC group. Doxorubicin was injected via the tail vein of each nonanesthetized mouse (10 mg/kg). Mice in the control group were treated with saline only. Body weights were 
MDSC Depletion Assay
MDSCs were depleted in vivo by intraperitoneal injections of 100 mg of a purified anti-mouse Ly-6G/Ly-6C (Gr-1, clone RB6-8C5) antibody (BD Biosciences) per mouse every 3 days. 36 Control mice were given equivalent amounts of purified rat IgG (BD Biosciences). The efficiency of antibody administration was confirmed by FACS.
Dexamethasone Treatment and Renal Function
Mice were divided into three groups (five mice in each group): (1) the control group (which received saline only), (2) the doxorubicin group (which received doxorubicin only), and (3) the doxorubicin+dexamethasone group. Doxorubicin was injected via the tail vein of each nonanesthetized mouse (10 mg/kg). Different concentrations of dexamethasone (0.1, 1, and 10 mg/kg) were injected intraperitoneally into mice each day. BM, blood, spleen, and kidney samples were obtained from mice in each group. Renal function was assessed by measuring urine albumin and creatinine. Urine was collected from each mouse for 24 hours. Urine albumin was measured using a mouse albumin ELISA kit (Bethyl Laboratories, Montgomery, TX). Urine and serum creatinine was determined as previously described. 57 
T Cell Proliferation Assays
To obtain high purity in MDSCs from PBMCs or spleen and KDLNs, a cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) was used according to the manufacturer's instructions. For the mouse T cell inhibition assay, splenocytes were first separated with lymphocyte separation medium. Lymphocytes were labeled with CFSE according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). CFSElabeled lymphocytes were stimulated with ConA (Sigma-Aldrich), and lymphocytes were co-cultured at 2:1 and 4:1 ratios with purified MDSCs in 96-well flat bottom plates. On the fourth day, the cultured cells were incubated with APC-conjugated anti-CD3 antibody. APCpositive cells were gated for further CFSE-labeled T cell proliferation analysis. For human HLA-DR 2 CD15 + cell inhibiting assay, anti-HLA-DR microbeads for the depletion of HLA-DR expressing cells from human peripheral blood and CD15-conjugated microbeads for positive selection of CD15 + cells from human peripheral blood were purchased from Miltenyi Biotec. T cells were sorted from PBMCs of healthy donors by anti-CD3 microbeads (Miltenyi Biotec), labeled with CFSE, and seeded in 96-well plates with HLA-DR 2 CD15 + cells at a 2:1 ratio. T cell proliferation was induced by anti-CD3/CD28 stimulation beads (Invitrogen). T cell proliferation was analyzed by flow cytometry on day 4.
Electron Microscopy Examination of the Kidney
Renal tissues (l mm 3 size) were fixed in cold 3.75% glutaraldehyde for
